Per report from an edwards lifesciences field representative, a leaflet of the sapien 3 ultra valve remained in the closed position out of the box.The valve did not come into contact with the patient, and a new valve was opened for the procedure.The device was evaluated by edwards lifesciences engineering and the following was observed: a crease on the commissure tab, a crease across the leaflet, and a crease at the scallop line.
|
A supplemental mdr is being submitted for correction and additional information based on the device evaluation.The following sections of this report have been updated: corrected h6: component codes, additional codes added to h6 type of investigation, corrected h6: investigation findings, corrected h6 investigation conclusions.The sapien 3 ultra valve was returned for evaluation.Visual evaluation of the valve revealed the following: creases present at commissure tabs, crease present across leaflet, crease present at "scallop" line.Functional testing of the device demonstrated that the valve opened and closed properly under the nominal stimulated physiological patient test conditions.A device history record (dhr) review was performed and did not reveal any manufacturing nonconformance that would have contributed to this complaint event.A review of the lot history revealed no other similar returned complaints for the trend categories.The instructions for use/training manuals were reviewed for guidance/instruction involving the sapien 3 ultra valve usage.Based on the review of the ifu/training manuals, no deficiencies were identified.A review of the risk management documentation was performed, and the reported event is an anticipated risk of the transcatheter heart valve procedure, additional assessment of the failure mode is not required at this time.The creases present on the valve were confirmed through evaluation of the device.Available information suggests a manufacturing issue may have contributed to the event.Complaint histories for all reported events are reviewed against trending control limits monthly, and any excursions above the control limits are assessed and documented as part of this monthly review.No ifu/labeling training manual inadequacies were identified.A product risk assessment was initiated to investigate the cause of the valve creases.A corrective action preventative action (capa) was initiated capture further investigation and to drive corrective actions.
|